Target intelligence / Profile preview

Other mRNAs with partial complementarity to ESOC1 siRNA seed region (ESOC1 siRNA off-targets)

Target
ESOC1 siRNA off-targets
Molecular classification
Messenger RNA (mRNA), Off-target transcripts
01

Overview

The term Other mRNAs with partial complementarity to ESOC1 siRNA seed region refers to a collection of non-target messenger RNA transcripts that are inadvertently silenced by small interfering RNAs (siRNAs) designed to target the ESOC1 gene (also known as DEPP1 or C10orf10). This phenomenon occurs because the seed region of an siRNA (nucleotides 2-8) can bind to the 3' untranslated regions (UTRs) of various mRNAs with partial complementarity, mimicking the regulatory mechanism of endogenous microRNAs [Birmingham, A., et al. (2006). Nature Methods, 3(3), 199-204]. ESOC1 is a protein primarily involved in the regulation of autophagy, response to oxidative stress, and hypoxia-induced pathways [UniProt Q96HI4]. When siRNAs are employed to study ESOC1 function, the unintended downregulation of these off-target mRNAs can lead to experimental artifacts or cellular toxicity, making it difficult to attribute observed phenotypes solely to ESOC1 knockdown. In the context of drug development, these off-targets represent a significant safety concern and a hurdle for the specificity of RNA interference (RNAi) therapeutics. Identifying and minimizing these interactions is essential for the design of high-specificity siRNA molecules and the accurate interpretation of biological data.

Other names
ESOC1 siRNA seed-mediated off-targetsC10orf10 siRNA off-target transcriptsDEPP1 siRNA off-targetsSeed-matched off-target genes for ESOC1 siRNA
02

Mechanism of action

Seed-mediated sequence-specific degradation or translational inhibition of non-target mRNAs via the RNA-induced silencing complex (RISC) [Jackson, A. L., et al. (2003). Nature Biotechnology, 21(6), 635-637].

03

Biological functions

Protein synthesisGene expression regulation
04

Disease associations

ToxicityOff-target effects
05

Safety considerations

Unintended gene silencingCytotoxicityPhenotypic confoundingOff-target toxicity in RNAi therapeutics
06

Interacting drugs

ESOC1 siRNA
07

Biomarkers

Transcriptome profilingRNA-seqReporter gene assays

Beyond the preview

Go deeper on Other mRNAs with partial complementarity to ESOC1 siRNA seed region (ESOC1 siRNA off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other mRNAs with partial complementarity to ESOC1 siRNA seed region (ESOC1 siRNA off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call